Management of Short Saphenous Vein Thrombosis Close to the Saphenopopliteal Junction: A Survey of the Membership of HaemSTAR, British Society for Haemostasis and Thrombosis and VTE Exemplar Centres in the United Kingdom

EJHaem Pub Date : 2025-04-26 DOI:10.1002/jha2.70037
Kirollos Salah Kamel, Lucy Wood, Nicola Curry
{"title":"Management of Short Saphenous Vein Thrombosis Close to the Saphenopopliteal Junction: A Survey of the Membership of HaemSTAR, British Society for Haemostasis and Thrombosis and VTE Exemplar Centres in the United Kingdom","authors":"Kirollos Salah Kamel,&nbsp;Lucy Wood,&nbsp;Nicola Curry","doi":"10.1002/jha2.70037","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The optimal management of superficial thrombophlebitis (STP) close to the saphenopopliteal junction (SPJ) is not known.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted an online survey of members of the HaemSTAR network, British society of haemostasis and thrombosis and UK VTE exemplar network over a 6-week period.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty-three respondents participated in the survey (estimated 22% response rate). Note that 89% of respondents indicated they would manage all STP at the SPJ with anticoagulation, with 70% indicating they would offer 3 months of therapeutic anticoagulation. The most common threshold for instigating anticoagulation was being within 3 cm off the SPJ (68%). Factors most associated with the decision to anticoagulate included previous thrombosis, active malignancy, persistent immobilisation and severe symptoms (with hospitalisation, hyperestrogenaemic states, thrombophilia and recent surgery being additionally identified in the non-treatment group).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Despite lack of evidence, most UK practitioners surveyed offered intermediate to treatment doses of anticoagulation in the case of STP within 3 cm of the SPJ. Further research is needed to assess the validity of this approach.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70037","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The optimal management of superficial thrombophlebitis (STP) close to the saphenopopliteal junction (SPJ) is not known.

Methods

We conducted an online survey of members of the HaemSTAR network, British society of haemostasis and thrombosis and UK VTE exemplar network over a 6-week period.

Results

Fifty-three respondents participated in the survey (estimated 22% response rate). Note that 89% of respondents indicated they would manage all STP at the SPJ with anticoagulation, with 70% indicating they would offer 3 months of therapeutic anticoagulation. The most common threshold for instigating anticoagulation was being within 3 cm off the SPJ (68%). Factors most associated with the decision to anticoagulate included previous thrombosis, active malignancy, persistent immobilisation and severe symptoms (with hospitalisation, hyperestrogenaemic states, thrombophilia and recent surgery being additionally identified in the non-treatment group).

Conclusion

Despite lack of evidence, most UK practitioners surveyed offered intermediate to treatment doses of anticoagulation in the case of STP within 3 cm of the SPJ. Further research is needed to assess the validity of this approach.

Trial Registration

The authors have confirmed clinical trial registration is not needed for this submission.

Abstract Image

靠近隐静脉连接处的短隐静脉血栓形成的处理:对HaemSTAR成员的调查,英国止血和血栓形成协会和VTE范例中心在英国
浅表性血栓性静脉炎(STP)靠近隐肾交界处(SPJ)的最佳治疗方法尚不清楚。方法:我们对HaemSTAR网络、英国止血与血栓学会和英国静脉血栓形成范例网络的成员进行了为期6周的在线调查。结果共有53人参与调查,估计回复率为22%。值得注意的是,89%的应答者表示他们会用抗凝治疗SPJ的所有STP, 70%的人表示他们会提供3个月的治疗性抗凝治疗。最常见的抗凝阈值是离SPJ 3cm以内(68%)。与抗凝决定最相关的因素包括既往血栓形成、活动性恶性肿瘤、持续不活动和严重症状(在非治疗组中,住院、高雌激素状态、血栓形成和近期手术也被确定)。结论:尽管缺乏证据,大多数接受调查的英国医生在距SPJ 3cm以内的STP病例中提供中间至治疗剂量的抗凝治疗。需要进一步的研究来评估这种方法的有效性。试验注册作者已确认该提交不需要临床试验注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信